Drug Trial Radar · NCT07517042
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jun 10, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.
Conditions
- Obesity
- Weight Control
Interventions
MazdutideDrug
Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.
Intensive Lifestyle InterventionBehavioral
Participants receive a structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.
Mazdutide PlaceboDrug
Mazdutide placebo is administered subcutaneously once weekly for 52 weeks during the weight maintenance period.
Usual Lifestyle CounselingBehavioral
Participants receive general health education and non-intensive lifestyle advice on healthy eating, physical activity, and weight management for 52 weeks during the weight maintenance period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change of body weightTime frame: From randomization to Week 52
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital (Xiamen), Fudan University
Xiamen, Fujia, China · Recruiting
Fujian Provincial Hospital, Affiliated to Fuzhou University
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
The Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University
Suzhou, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Huadong Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai General Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tenth People's Hospital, School of Medicine, Tongji University
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.